NVIDIA
NVDA
Tesla
TSLA
Disney
DIS
Apple
AAPL
Netflix
NFLX
US Stock MarketDetailed Quotes
AMRN Amarin
- 0.542
- -0.009-1.65%
Close Feb 28 16:00 ET
- 0.553
- +0.011+2.03%
Post 19:54 ET
222.90MMarket Cap-5.42P/E (TTM)
0.558High0.523Low806.72KVolume0.558Open0.551Pre Close437.30KTurnover0.21%Turnover RatioLossP/E (Static)411.34MShares1.11052wk High0.42P/B207.83MFloat Cap0.43052wk Low--Dividend TTM383.52MShs Float675.000Historical High--Div YieldTTM6.41%Amplitude0.430Historical Low0.542Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Amarin Stock Forum
Can This Cardiovascular Drug Work Where Others Fall Short? New REDUCE-IT Data Reveals 34% Event Reduction
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
Thursday, 27th February at 9:00 am
-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Very Well-Controlled Low-Density Lipo...
undervalued, oversold
C&E: 156M ST Debt: 9.5M, LT Debt: 8.88M CR: 3.2 QR: 2.08 FCF: -18M
The risk of dilution is low for now. However, cash burn is problematic. Expanded to Euro markets w/2039 patent expiry
Amarin Receives National Reimbursement for VAZKEPA® in Italy
Monday, 16th December at 7:00 am
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients1 --
-- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursement for VAZKEPA® Overall in Europe --
-- European Progress Has Advanced Patient Access: Countries That Have Provided Access to VAZKEP...
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 22, 2024, Amarin Corporation plc (the “Company”) received a notice (the “Extension Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until May 19, 2025, to regain compliance with the minimum bid price requi...
No comment yet